Joseph P. Lyssikatos
Nivalis Therapeutics (United States)(US)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Chronic Myeloid Leukemia Treatments, Protein Kinase Regulation and GTPase Signaling, HER2/EGFR in Cancer Research, Chemical Synthesis and Analysis
Most-Cited Works
- → Novel antibody–antibiotic conjugate eliminates intracellular S. aureus(2015)820 cited
- → Effect of selective LRRK2 kinase inhibition on nonhuman primate lung(2015)364 cited
- → Discovery of Highly Potent, Selective, and Brain-Penetrable Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule Inhibitors(2012)161 cited
- → Antiangiogenic and Antitumor Activity of a Selective PDGFR Tyrosine Kinase Inhibitor, CP-673,451(2005)135 cited
- → The Mutant p53-Conformation Modifying Drug, CP-31398, Can Induce Apoptosis(2002)128 cited
- → Discovery of Highly Potent, Selective, and Brain-Penetrant Aminopyrazole Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule Inhibitors(2013)123 cited
- → Lead Optimization of a 4-Aminopyridine Benzamide Scaffold To Identify Potent, Selective, and Orally Bioavailable TYK2 Inhibitors(2013)97 cited
- → Discovery of Potent and Selective Pyrazolopyrimidine Janus Kinase 2 Inhibitors(2012)89 cited
- → Discovery of Dual Leucine Zipper Kinase (DLK, MAP3K12) Inhibitors with Activity in Neurodegeneration Models(2014)86 cited
- → Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-p K a Polar Moiety(2015)83 cited